Cadrenal Therapeutics Achieves ISTH 2026 Selection for CAD-1005 Phase 2 Data in Heparin-Induced Thrombocytopenia

Phase 2 data for CAD-1005, Cadrenal Therapeutics' first-in-class 12-lipoxygenase inhibitor, will reach a global clinical audience on July 12, 2026, when the compound's principal investigator presents findings at the ISTH Congress in Paris, the first randomized, blinded, placebo-controlled trial ever conducted in heparin-induced thrombocytopenia (HIT). For hospital pharmacists, formulary committees, and QA leads tracking anticoagulation pipelines, the presentation marks the earliest credible signal of a mechanism-targeted therapy entering a space where no approved agent currently addresses antibody-mediated platelet activation.

HIT is an immune-mediated prothrombotic reaction in which antibodies against platelet factor 4-heparin complexes activate platelets via FcγRIIA receptors. Current standard of care relies on non-heparin anticoagulants that reduce thrombin generation but leave the underlying platelet activation pathway unaddressed, meaning new thrombosis remains a clinical risk even under appropriate anticoagulant therapy. CAD-1005 is designed to selectively inhibit 12-LOX, the enzyme central to that immune-activation cascade, and is intended for use alongside existing standards of care rather than as a replacement.

The abstract, titled 12-lipoxygenase inhibition with VLX-1005 in heparin-induced thrombocytopenia, was selected by peer reviewers for the Late-Breakthrough Abstracts I: Clinical Trials and Innovation in Thrombosis session at the 34th ISTH Congress, running July 11–15 at the Palais des Congrès de Paris. Dr. Steve McKenzie, Professor of Medicine at Thomas Jefferson University and principal investigator, will deliver the oral presentation. Cadrenal describes the program as Phase 3-ready and has cited peak annual revenue potential of $2 billion in the HIT market, though those projections carry the standard uncertainties of pre-approval pipeline assets.

For manufacturing and supply-chain planners, the Phase 3 readiness claim is the operative signal. A positive Phase 2 readout at ISTH, presented to the leading international thrombosis and haemostasis audience, would accelerate the timeline for process validation planning, clinical supply scaling, and eventual 21 CFR Part 211-compliant commercial manufacturing discussions. The compound's selectivity profile and adjunctive positioning alongside existing anticoagulants also carry formulary and pharmacovigilance implications that hospital QA teams will want to track ahead of any Phase 3 IND amendments.

The measurable checkpoint is the July 12 session data readout, which will determine whether CAD-1005's Phase 2 efficacy and safety profile supports the Phase 3 design assumptions Cadrenal has signaled to the market.

Source: Cadrenal Therapeutics, Inc. via GlobeNewswire, June 24, 2026.